Evidence map›Paper›PMID 32365251›Full record

Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2021

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).

J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi and 1 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02826603 (A 52-week, Randomized, Double-blind Study of Secukinumab), which is not on this map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02826603 phase3completednot on this map

A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2018Enrolled1,114ConditionsPlaque PsoriasisArmsSecukinumab, Ustekinumab
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

J BagelPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA.ORCID https://orcid.org/0000-0001-5241-0915
A BlauveltOregon Medical Research Center, Portland, OR, USA.ORCID https://orcid.org/0000-0002-2633-985X
J NiaIcahn School of Medicine at Mount Sinai, New York, NY, USA.
P HashimIcahn School of Medicine at Mount Sinai, New York, NY, USA.
M PatekarNovartis Pharma AG, Basel, Switzerland.
A de VeraNovartis Pharma AG, Basel, Switzerland.
K AhmadNovartis Healthcare Pvt Ltd, Hyderabad, India.
B PaguetNovartis Pharma AG, Basel, Switzerland.
S XiaBeijing Novartis Pharma Co, Ltd, Shanghai, China.
E MuscianisiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
M LebwohlIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USNovartis (Switzerland) · CHNovartis (China) · CNNovartis (India) · INNovartis (United States) · USOregon Medical Research Center · USVA New Jersey Health Care System · US

Funding

Novartis Pharma AG
6 · The paper itself

Abstract

backgroundSecukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study.

objectiveTo compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARITY.

methodsAnalysis of 52-week data from CLARITY (NCT02826603), a phase 3b study in which patients were randomized to receive secukinumab 300 mg (n = 550) or ustekinumab 45/90 mg (n = 552) per label.

resultsAt week 52, secukinumab was superior to ustekinumab in the proportion of patients who achieved ≥ 90% improvement in Psoriasis Area and Severity Index (73.2% vs. 59.8%; odds ratio [OR], 1.84 [95% CI, 1.41-2.41]; P < 0.0001), Investigator's Global Assessment modified 2011 responses of clear (0) or almost clear (1) skin (76.0% vs. 60.2%; OR, 2.12 [95% CI, 1.61-2.79]; P < 0.0001) and Dermatology Life Quality Index response of no effect (0/1) (69.9% vs. 61.2%; P = 0.0028). Proportions of patients with any adverse events were comparable between treatment arms.

conclusionsThis second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Clinicaltrials.gov identifier: NCT02826603.

Indexed as

Dermatologic AgentsPsoriasisAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDouble-Blind MethodHumansQuality of LifeSeverity of Illness IndexTreatment OutcomeUstekinumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentssecukinumabUstekinumab

Identifiers

PMID32365251
PMCPMC7818402
OpenAlexW3022612060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.